23andMe (NASDAQ:ME – Get Free Report) posted its quarterly earnings data on Tuesday. The company reported ($1.02) earnings per share (EPS) for the quarter, Zacks reports. 23andMe had a negative return on equity of 129.98% and a negative net margin of 318.39%.
23andMe Stock Performance
23andMe stock opened at $3.40 on Wednesday. 23andMe has a 12 month low of $2.65 and a 12 month high of $16.52. The company’s fifty day simple moving average is $3.46 and its 200-day simple moving average is $5.36.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings restated a “sell (e+)” rating on shares of 23andMe in a research report on Saturday, January 18th.
23andMe Company Profile
23andMe Holding Co operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications.
Featured Stories
- Five stocks we like better than 23andMe
- P/E Ratio Calculation: How to Assess Stocks
- Why Salesforce Stock Could Be at Fresh Highs by February
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Talos Energy: Time to Take a Plunge Ahead of New CEO Appointment?
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Oklo’s Fuel Partnership Strengthens Bullish Case for Stock
Receive News & Ratings for 23andMe Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 23andMe and related companies with MarketBeat.com's FREE daily email newsletter.
